Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Acquires Narus Biotechnologies

NEW YORK (GenomeWeb) – RNA products developer Cofactor Genomics announced today that it has acquired San Francisco-based biomarker development company Narus Biotechnologies.

The acquisition of Narus — which has been focused on creating RNA-based diagnostics for neurological diseases such as Alzheimer's and Parkinson's — will help Cofactor to further expand into the realm of RNA diagnostics, and to develop its plans to create RNA-based tests for cancer and neurodegenerative diseases, the company said.

Terms of the deal were not disclosed.

"In addition to acquiring Narus' assets related to RNA biomarkers, we gain an extremely talented team that is already helping to accelerate Cofactor's RNA-based diagnostic roadmap," said Cofactor CEO Jarret Glasscock in a statement. "This acquisition … secures the resources necessary to change the face of medicine by using RNA to detect disease and monitor treatment progression."

Over the past two years, Cofactor has received at least two NIH grants to develop circular RNA enrichment technology and companion data analysis software to detect circRNA as a possible biomarker for psychiatric disorders.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.